Original

Uriach is an international pharmaceutical company specializing in Natural Consumer Healthcare, with a history spanning over 185 years and six generations of family ownership. Headquartered in Barcelona, Spain, it is one of the oldest laboratories in Spain and the second oldest in Europe. The company is currently focused on products that combine natural ingredients with scientific innovation to improve human health and well-being. Core Business Areas Uriach operates primarily in the natural self-care market through two main avenues: Consumer Healthcare (B2C): This includes over-the-counter (OTC) pharmaceuticals, food supplements, and natural care products. Business to Business (B2B): The company provides contract manufacturing services (CDMO) for solid oral dosages (tablets, pills) and semisolids (creams, ointments), as well as development for generics and new chemical entities (NCEs). Product Portfolio and Iconic Brands Uriach manages a "house of brands" across various therapeutic categories such as sleep and relaxation, muscle wellness, and respiratory health: Aquilea: A Spanish leader in natural food supplements. Fisiocrem: Natural solutions for joint and muscle treatment. Laborest: Sophisticated nutraceuticals primarily marketed in Italy. Sidroga: Medicinal teas, a leader in the DACH market (Germany, Austria, Switzerland). Pediakid: A leading French brand for natural children's health products. Other Well-Known Brands: Biodramina (transport sickness leader in Spain), Aero-red (bloating relief), Halibut (skin regeneration), and Utabon (nasal congestion). Strategic Growth and Market Presence The company has undergone a major strategic transformation over the last decade, shifting from a traditional pharmaceutical focus toward Natural Consumer Healthcare. International Reach: Uriach has a direct presence in 11 European countries, including Spain, Italy, Portugal, Germany, Austria, Switzerland, Romania, France, Belgium, Czech Republic, and Slovakia. Global Distribution: Its products are distributed in over 80 countries. Financials: In 2024, Uriach reported turnover exceeding 476 million euros, a 54% increase from the previous year, with an EBITDA of over 74 million euros. Acquisitions: Growth is driven by aggressive inorganic expansion, including recent 2024 acquisitions of Pascoe (Germany) and Laboratories Ineldéa (France). Corporate Governance and Values B Corp Certification: Uriach is a certified B Corp, meeting high standards of social and environmental performance and transparency. Governance Model: It maintains an independent family structure but is managed by a professional leadership team designed to balance family, property, and business interests. Workforce: As of 2025, the company has approximately 1,300 to 1,400 collaborators. Facilities: Its primary production and research facility is a 30,000 m² plant in Palau-solità i Plegamans, Barcelona, which operates according to GMP/GLP standards.